Sensitivity analyses for effect modifiers not observed in the target population when generalizing treatment effects from a randomized controlled trial: Assumptions, models, effect scales, data scenarios, and implementation details
暂无分享,去创建一个
Ian Schmid | Stephen R Cole | Elizabeth A Stuart | Benjamin Ackerman | Trang Quynh Nguyen | S. Cole | E. Stuart | I. Schmid | B. Ackerman | T. Nguyen
[1] M A Fischl,et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.
[2] Geoffrey D. Borman,et al. Site Selection in Experiments: An Assessment of Site Recruitment and Generalizability in Two Scale-up Studies , 2016 .
[3] Howard S. Bloom,et al. A Conceptual Framework for Studying the Sources of Variation in Program Effects , 2013 .
[4] S. Schneeweiss,et al. From Trial to Target Populations - Calibrating Real-World Data. , 2017, The New England journal of medicine.
[5] Lisa M. Lee,et al. Estimation of HIV incidence in the United States. , 2008, JAMA.
[6] Eloise E Kaizar,et al. The use of propensity scores and observational data to estimate randomized controlled trial generalizability bias , 2013, Statistics in medicine.
[7] S. Cole,et al. Correction: Sensitivity analysis for an unobserved moderator in RCT-to-target-population generalization of treatment effects , 2016, The Annals of Applied Statistics.
[8] Michael J. Weiss,et al. A CONCEPTUAL FRAMEWORK FOR STUDYING THE SOURCES OF VARIATION IN PROGRAM EFFECTS: Sources of Variation in Program Effects , 2014 .
[9] Eloise E Kaizar. Estimating treatment effect via simple cross design synthesis , 2011, Statistics in medicine.
[10] Michael G Hudgens,et al. Generalizing Study Results: A Potential Outcomes Perspective. , 2017, Epidemiology.
[11] J. Ware,et al. Detecting Moderator Effects Using Subgroup Analyses , 2013, Prevention Science.
[12] E. Stuart,et al. Generalizing Treatment Effect Estimates From Sample to Population: A Case Study in the Difficulties of Finding Sufficient Data , 2017, Evaluation review.
[13] Elizabeth Tipton. Improving Generalizations From Experiments Using Propensity Score Subclassification , 2013 .
[14] Ravi Varadhan,et al. A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. , 2013, Journal of clinical epidemiology.
[15] D. Rubin. Estimating causal effects of treatments in randomized and nonrandomized studies. , 1974 .
[16] Alex H. S. Harris,et al. Influence of subject eligibility criteria on compliance with National Institutes of Health guidelines for inclusion of women, minorities, and children in treatment research. , 2007, Alcoholism, clinical and experimental research.
[17] Stephen R Cole,et al. Transportability of Trial Results Using Inverse Odds of Sampling Weights. , 2017, American journal of epidemiology.
[18] Catherine P. Bradshaw,et al. Assessing the Generalizability of Randomized Trial Results to Target Populations , 2015, Prevention Science.
[19] Jennifer Hill,et al. Assessing Methods for Generalizing Experimental Impact Estimates to Target Populations , 2016, Journal of research on educational effectiveness.
[20] David M Kent,et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal , 2010, Trials.
[21] S. Cole,et al. Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial. , 2010, American journal of epidemiology.
[22] S. Cole,et al. Causal Impact: Epidemiological Approaches for a Public Health of Consequence. , 2016, American journal of public health.